Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy

P. Pane, R. Arcieri, M. Bonati, M. Bugarini, A. Didoni, E. Germinario

Research output: Contribution to journalArticlepeer-review

Abstract

The drugs prescribed to treat attention-deficit/hyperactivity disorder, one of the most prevalent psychiatric disease affecting children and adolescents, may risk causing harm. Recently, the U.S. Food and Drug Administration (FDA) has warned about liver and cardiovascular risks, and the European Medicines Agency (EMEA) had performed an assessment of risk-benefit ratio of psychostimulants. Pharmacovigilance in an Italian population aged 6-17 years suggests that atomoxetine is more likely to be reported as causing harm than methylphenidate.

Original languageEnglish
Pages (from-to)999-1002
Number of pages4
JournalAdverse Drug Reaction Bulletin
Issue number260
Publication statusPublished - Feb 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy'. Together they form a unique fingerprint.

Cite this